Biomerica, Inc. is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on products for Gastrointestinal Disease, Diabetes and esoteric testing.
Company profile
Ticker
BMRA
Exchange
Website
CEO
Zackary S. Irani
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NMS PHARMACEUTICALS INC, NUCLEAR MEDICAL SYSTEMS INC, NUCLEAR INSTRUMENTS INC
SEC CIK
Corporate docs
Subsidiaries
BioEurope GmbH • Biomerica de Mexico ...
IRS number
952645573
BMRA stock data
News
Stocks That Hit 52-Week Lows On Wednesday
20 Jul 22
Stocks That Hit 52-Week Lows On Tuesday
19 Jul 22
Why Cannabis Companies Traded Higher; Here's 60 Biggest Movers From Yesterday
15 Jul 22
Nasdaq Turns Positive; Morgan Stanley Posts Weak Q2 Earnings
14 Jul 22
Dow Tumbles 450 Points; JPMorgan Shares Drop Following Earnings Miss
14 Jul 22
Investment data
Securities sold
Number of investors
Calendar
14 Apr 22
12 Aug 22
31 May 23
Financial summary
| Quarter (USD) | Feb 22 | Nov 21 | Aug 21 | May 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | May 21 | May 20 | May 19 | May 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 10.17M | 10.17M | 10.17M | 10.17M | 10.17M | 10.17M |
| Cash burn (monthly) | (no burn) | (no burn) | 35.83K | 374.99K | (no burn) | (no burn) |
| Cash used (since last report) | n/a | n/a | 197.1K | 2.06M | n/a | n/a |
| Cash remaining | n/a | n/a | 9.98M | 8.11M | n/a | n/a |
| Runway (months of cash) | n/a | n/a | 278.4 | 21.6 | n/a | n/a |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 20 Dec 21 | Barbieri Allen | Common Stock | Gift | Dispose G | No | No | 0 | 7,500 | 0 | 107,289 |
| 9 Dec 21 | Catherine Coste | NQSO Common Stock | Grant | Acquire A | No | No | 4.46 | 25,000 | 111.5K | 70,000 |
| 9 Dec 21 | Jane Emerson | NQSO Common Stock | Grant | Acquire A | No | No | 4.46 | 25,000 | 111.5K | 190,000 |
| 9 Dec 21 | Barbieri Allen | NQSO Common Stock | Grant | Acquire A | No | No | 4.46 | 45,000 | 200.7K | 265,000 |
| 9 Dec 21 | Sirgo Mark A | NQSO Common Stock | Grant | Acquire A | No | No | 4.46 | 25,000 | 111.5K | 170,000 |
Institutional ownership, Q1 2022
19.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 28 |
| Opened positions | 2 |
| Closed positions | 2 |
| Increased positions | 8 |
| Reduced positions | 5 |
| 13F shares | Current |
|---|---|
| Total value | 11.26M |
| Total shares | 2.52M |
| Total puts | 0 |
| Total calls | 126.2K |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Granahan Investment Management | 1.17M | $5.23M |
| Vanguard | 545.95K | $2.44M |
| BLK Blackrock | 183.93K | $821K |
| Fore Capital | 85K | $380K |
| Geode Capital Management | 77.25K | $345K |
| Heritage Investors Management | 69.35K | $310K |
| Ridgewood Investments | 60K | $268K |
| STT State Street | 55.83K | $250K |
| GWM Advisors | 32.9K | $147K |
| Citadel Advisors | 32.81K | $147K |
Financial report summary
?Management Discussion
- ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
- You should read the following discussion and analysis in conjunction with our consolidated financial statements and the accompanying notes thereto included in Part II, Item 8 of this Report. This discussion and analysis contains forward-looking statements that are based on our management’s current beliefs and assumptions, which statements are subject to substantial risks and uncertainties. Our actual results may differ materially from those expressed or implied by these forward-looking statements as a result of many factors, including those discussed in “Risk Factors” included in Part I, Item 1A of this Report.
- Biomerica, Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH), is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (physicians' offices and over-the-counter through drugstores and online) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. Our diagnostic test kits are used to analyze blood, urine, nasal or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs.
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
abdominal, bloating, calendar, comment, evidence, found, greatest, guided, institution, intention, line, meaningfully, multinational, Multiple, Organization, pain, pathway, pivotal, return, selecting, statistically, study, symptom, target, top
Removed:
announcement, CEO, cooperated, December, Division, enforcement, exclusive, fully, implemented, investigation, Irani, leading, notice, obtaining, personal, produced, rapid, requesting, review, subpoena, system, Zack
Financial reports
Current reports
8-K
Changes in Registrant's Certifying Accountant
19 Apr 22
8-K
Regulation FD Disclosure
10 Feb 22
8-K
Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to approximately $4.6 Million
16 Dec 21
8-K
Submission of Matters to a Vote of Security Holders
10 Dec 21
8-K
Other Events
7 Dec 21
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
30 Sep 21
8-K
Regulation FD Disclosure
24 Jun 21
8-K
Other Events
22 Jan 21
8-K
Biomerica’S Fast 15-Minute Simple to use COVID-19 Antigen RAPID test receives CE Mark
13 Jan 21
8-K
Submission of Matters to a Vote of Security Holders
11 Dec 20
Registration and prospectus
S-8
Registration of securities for employees
21 May 21
424B5
Prospectus supplement for primary offering
22 Jan 21
S-3/A
Shelf registration (amended)
11 Sep 20
424B5
Prospectus supplement for primary offering
20 Mar 20
D
$2M in equity, sold $2M, 1 investor
27 Feb 20
S-8
Registration of securities for employees
10 May 18
424B5
Prospectus supplement for primary offering
3 Dec 17
S-3
Shelf registration
29 Jun 17
8-A12B
Registration of securities on exchange
22 Aug 16
Other
EFFECT
Notice of effectiveness
1 Oct 20
CORRESP
Correspondence with SEC
27 Sep 20
CORRESP
Correspondence with SEC
10 Sep 20
CORRESP
Correspondence with SEC
8 Sep 20
UPLOAD
Letter from SEC
27 Jul 20
EFFECT
Notice of effectiveness
19 Jul 17
CORRESP
Correspondence with SEC
17 Jul 17
UPLOAD
Letter from SEC
5 Jul 17
UPLOAD
Letter from SEC
16 Mar 09
CORRESP
Correspondence with SEC
15 Mar 09
Ownership
5
BIOMERICA / ALLEN BARBIERI ownership change
24 Jun 22
SC 13G
BIOMERICA / Granahan Investment Management ownership change
13 Feb 22
SC 13G/A
BIOMERICA / WELLINGTON MANAGEMENT ownership change
4 Feb 22
SC 13G/A
BIOMERICA / WELLINGTON TRUST Co N A ownership change
4 Feb 22
SC 13G/A
BIOMERICA / Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio ownership change
4 Feb 22
4
BIOMERICA / Zackary S. Irani ownership change
10 Dec 21
4
BIOMERICA / Steven Sloan ownership change
10 Dec 21
4
BIOMERICA / Mark A Sirgo ownership change
10 Dec 21
4
BIOMERICA / ALLEN BARBIERI ownership change
10 Dec 21
4
BIOMERICA / Jane Emerson ownership change
10 Dec 21
Patents
Utility
Compositions, Devices, and Methods of Ibs Sensitivity Testing
10 Jun 21
Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value.
Utility
IBS sensitivity testing
28 Sep 20
Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value.
Utility
Compositions, Devices, and Methods of Attention Deficit Disorder/attention Deficit Hyperactivity Disorder (Add/adhd) Sensitivity Testing
1 Jan 20
Contemplated test kits, diagnostic apparatus and methods using same for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value.
Reddit threads
Walmart to Begin Selling Biomerica’s Aware® Breast Self Exam $BMRA *This Is Huge* Low Float Massive News!
14 Jul 22
Walmart to Begin Selling Biomerica’s Aware® Breast Self Exam $BMRA
14 Jul 22
Daily Plays July 07, 2022
7 Jul 22
HCDI and BMRA. two low float undervalued stocks I think need more consideration
10 Jun 22
Daily Discussion Thread - April 13th, 2022
13 Apr 22
Daily Discussion Thread - April 12th, 2022
12 Apr 22
Daily Discussion Thread - April 11th, 2022
11 Apr 22
Where are people putting their cash?
22 Feb 22
ARKK is a helluva drug
18 Feb 22
Palantir Technologies Non-GAAP EPS of $0.02 misses by $0.02, revenue of $432.8M beats by $14.73M
17 Feb 22